Skip to main content

Advertisement

SpringerLink
Log in

Short-Term Safety Evaluation of Albumin-Bound Paclitaxel in Intraoperative and Postoperative Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer

  • Research
  • Published:
Journal of Gastrointestinal Cancer Aims and scope Submit manuscript

Abstract

Purpose

To evaluate the short-term safety of albumin-bound paclitaxel in hyperthermic intraperitoneal chemotherapy (HIPEC) during and after gastric cancer (GC) surgery.

Methods

A retrospective analysis of clinical data was conducted for GC surgery patients at Zhongnan Hospital of Wuhan University, from January 2020 to September 2022. The study group (n = 120) received HIPEC and the control group (n = 268) did not receive albumin-bound paclitaxel. Short-term safety indicators including intraoperative complications, hematological toxicity, liver and kidney function, and gastrointestinal function recovery were compared between the two groups.

Results

There were no statistically significant differences between the two groups regarding intraoperative complications, hematological toxicity, liver and kidney function, and gastrointestinal function recovery time (P > 0.05 for all). In the study group, patients were further divided into subgroups based on dose and timing. Subgroup analysis revealed no significant differences among the different dose subgroups. However, when focusing on timing subgroups, the postoperative subgroup exhibited significantly higher white blood cell counts and bilirubin levels compared to the intraoperative subgroup, while the intraoperative subgroup had significantly higher bilirubin levels compared to both postoperative and intraoperative plus postoperative subgroups.

Conclusion

Albumin-bound paclitaxel demonstrates good safety and tolerability in HIPEC during and after GC surgery, without increasing the risk of intraoperative complications.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

Data Availability

The datasets generated during and analyzed during the current study are available from the corresponding author on reasonable request.

References

  1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.

    Article  PubMed  Google Scholar 

  2. Sexton RE, Al Hallak MN, Diab M, Azmi AS. Gastric cancer: a comprehensive review of current and future treatment strategies. Cancer Metastasis Rev. 2020;39(4):1179–203.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Rijken A, Lurvink RJ, Luyer MDP, Nieuwenhuijzen GAP, van Erning FN, van Sandick JW, de Hingh IHJT. The burden of peritoneal metastases from gastric cancer: a systematic review on the incidence, risk factors and survival. J Clin Med. 2021;10(21):4882.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Wang Z, Chen J, Liu J, Tian L. Issues on peritoneal metastasis of gastric cancer: an update. World J Surg Oncol. 2019;17(1):215.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Yonemura Y, Ishibashi H, Mizumoto A, Tukiyama G, Liu Y, Wakama S, et al. The development of peritoneal metastasis from gastric cancer and rationale of treatment according to the mechanism. J Clin Med. 2022;11(2):458.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Liu M, Silva-Sanchez A, Randall TD, Meza-Perez S. Specialized immune responses in the peritoneal cavity and omentum. J Leukoc Biol. 2021;109(4):717–29.

    Article  CAS  PubMed  Google Scholar 

  7. Ji ZH, Zhang Y, Li Y. Intra-operative hyperthermic intraperitoneal chemotherapy for prevention and treatment of peritoneal metastases from gastric cancer: a narrative review. J Gastrointest Oncol. 2021;12(S1):S70–8.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Ma R, Ji ZH, Zhang Y, Li Y. Fundamental pathological mechanisms underlying gastro-intestinal cancer peritoneal metastasis. Zhonghua Wei Chang Wai Ke Za Zhi. 2021;24(3):198–203.

    CAS  PubMed  Google Scholar 

  9. Khan H, Johnston FM. Current role for cytoreduction and HIPEC for gastric cancer with peritoneal disease. J Surg Oncol. 2022;125(7):1176–82.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Zhang Y, Wu Y, Wu J, Wu C. Direct and indirect anticancer effects of hyperthermic intraperitoneal chemotherapy on peritoneal malignancies (Review). Oncol Rep. 2021;45(4):1–1.

    Article  MathSciNet  PubMed  PubMed Central  ADS  Google Scholar 

  11. Bonnot PE, Piessen G, Kepenekian V, Decullier E, Pocard M, Meunier B, et al. Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy for gastric cancer with peritoneal metastases (CYTO-CHIP study): a propensity score analysis. J Clin Oncol. 2019;37(23):2028–40.

    Article  CAS  PubMed  Google Scholar 

  12. Hsu A, Raufi AG. Advances in systemic therapy for gastric cancer. Gastrointest Endosc Clin N Am. 2021;31(3):607–23.

    Article  PubMed  Google Scholar 

  13. Yildirim S, Yilmaz C. Triplet or doublet chemotherapy regimens in metastatic gastric cancer. Clin Cancer Investig J. 2022;11(3):41–5.

    Article  MathSciNet  Google Scholar 

  14. Roviello G, Conter FU, Mini E, Generali D, Traversini M, Lavacchi D, et al. Nanoparticle albumin-bound paclitaxel: a big nano for the treatment of gastric cancer. Cancer Chemother Pharmacol. 2019;84(4):669–77.

    Article  CAS  PubMed  Google Scholar 

  15. Cirauqui BC, García VQ, Rubio CL, Miguel MI, Riera LC, Aranda NP, et al. Nanoparticle albumin-bound paclitaxel in a patient with locally advanced breast cancer and taxane-induced skin toxicity: a case report. J Med Case Rep. 2014;8(1):6.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Zhang J, Li L, Yin J, Zhang X, Zheng Y, Feng R. Study on the thermal stability of nab-paclitaxel during hyperthermic intraperitoneal chemotherapy. BMC Pharmacol Toxicol. 2023;24(1):13.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Shi W, Wan X, Wang Y, He J, Huang X, Xu Y, et al. Nanoparticle albumin-bound paclitaxel-based neoadjuvant regimen: a promising treatment option for HER2-low-positive breast cancer. Nanomedicine. 2023;49: 102666.

    Article  CAS  PubMed  Google Scholar 

  18. Wang S, Liang Q, Chi Y, Zhuo M, An T, Duan J, et al. Retrospective analysis of the effectiveness and tolerability of nab-paclitaxel in Chinese elderly patients with advanced non-small-cell lung carcinoma. Thorac Cancer. 2020;11(5):1149–59.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Sakaue T, Fukahori M, Miwa K, Ushijima T, Yasumoto M, Kuraoka K, et al. Combined therapy with gemcitabine hydrochloride and nanoparticle albumin-bound paclitaxel enabled resection in a patient with unresectable locally advanced pancreatic cancer. Pancreas. 2019;48(6):859–859.

    Google Scholar 

  20. Bando H, Shimodaira H, Fujitani K, Takashima A, Yamaguchi K, Nakayama N, et al. A phase II study of nab-paclitaxel in combination with ramucirumab in patients with previously treated advanced gastric cancer. Eur J Cancer. 2018;91:86–91.

    Article  CAS  PubMed  Google Scholar 

  21. Zhu M, Zhang P, Yu S, Tang C, Wang Y, Shen Z, et al. Targeting ZFP64/GAL-1 axis promotes therapeutic effect of nab-paclitaxel and reverses immunosuppressive microenvironment in gastric cancer. J Exp Clin Canc Res. 2022;41(1):14.

    Article  CAS  Google Scholar 

  22. Awasthi N, Schwarz MA, Zhang C, Schwarz RE. Augmentation of nab-paclitaxel chemotherapy response by mechanistically diverse antiangiogenic agents in preclinical gastric cancer models. Mol Cancer Ther. 2018;17(11):2353–64.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Chinese Peritoneal Cancer Association, Professional Committee of Tumor Hyperthermia of Guangdong Anticancer Association. Chinese expert concensus on clinical application of hyperthermic intraperitoneal chemotherapy (2019 edition). Natl Med J China. 2020;100(2):89–96.

  24. Koemans WJ, Luijten JCHBM, van der Kaaij RT, Grootscholten C, Snaebjornsson P, Verhoeven RHA, et al. The metastatic pattern of intestinal and diffuse type gastric carcinoma – a Dutch national cohort study. Cancer Epidemiol. 2020;69:101846.

  25. Sugarbaker PH. Prevention and treatment of peritoneal metastases: a comprehensive review. Indian J Surg Oncol. 2019;10(1):3–23.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Sirody J, Kaji AH, Hari DM, Chen KT. Patterns of gastric cancer metastasis in the United States. Am J Surg. 2022;224(1):445–8.

    Article  PubMed  Google Scholar 

  27. Koemans WJ, Luijten JCHBM, van der Kaaij RT, Grootscholten C, Snaebjornsson P, Verhoeven RHA, van Sandick JW. The metastatic pattern of intestinal and diffuse type gastric carcinoma – a Dutch national cohort study. Cancer Epidemiol. 2020;69:101846.

  28. Prabhu A, Mishra D, Brandl A, Yonemura Y. Gastric cancer with peritoneal metastasis—a comprehensive review of current intraperitoneal treatment modalities. Front Oncol. 2022;12: 864647.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Ji ZH, Peng KW, Yu Y, Li XB, Yonemura Y, Liu Y, Sugarbaker PH, Li Y. Current status and future prospects of clinical trials on CRS + HIPEC for gastric cancer peritoneal metastases. Int J Hyperthermia. 2017;33(5):562–70.

    Article  PubMed  Google Scholar 

  30. Rau B, Feldbrügge L, Gronau F, Vilchez MEA, Thuss-Patience P, Bonnot PE, et al. Indication of hyperthermic intraperitoneal chemotherapy in gastric cancer (gastripec, gastrichip). Visc Med. 2022;38(2):81–9.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Brenkman HJF, Päeva M, van Hillegersberg R, Ruurda JP, Haj MN. Prophylactic hyperthermic intraperitoneal chemotherapy (HIPEC) for gastric cancer—a systematic review. J Clin Med. 2019;8(10):1685.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Gronau F, Feldbruegge L, Oberwittler F, Gonzalez-Moreno S, Villeneuve L, Eveno C, Glehen O, Kusamura S, Rau B. HIPEC in peritoneal metastasis of gastric origin: a systematic review of regimens and techniques. J Clin Med. 2022;11(5):1456.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Zhang JF, Lv L, Zhao S, Zhou Q, Jiang CG. Hyperthermic intraperitoneal chemotherapy (HIPEC) combined with surgery: a 12-year meta-analysis of this promising treatment strategy for advanced gastric cancer at different stages. Ann Surg Oncol. 2022;29(5):3170–86.

    Article  PubMed  Google Scholar 

  34. Brandl A, Yonemura Y, Glehen O, Sugarbaker P, Rau B. Long term survival in patients with peritoneal metastasised gastric cancer treated with cytoreductive surgery and HIPEC: a multi-institutional cohort from PSOGI. Eur J Surg Oncol. 2021;47(1):172–80.

    Article  PubMed  Google Scholar 

  35. Praiss AM, Moukarzel LA, Zivanovic O. Is there a role for hyperthermic intraperitoneal chemotherapy in ovarian cancer? Curr Opin Obstet Gynecol. 2023;35(1):21–6.

    Article  PubMed  Google Scholar 

  36. Frühling P, Ghanipour L, Dranichnikov P, Enblad M, Birgisson H, Cashin PH. Oxaliplatin-based hyperthermic intraperitoneal chemotherapy with single drug versus multiple drug treatment for colorectal cancer with peritoneal metastases: an observational cohort study. J Gastrointest Oncol. 2021;12(2):516–26.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Sugarbaker PH. Intraperitoneal paclitaxel: pharmacology, clinical results and future prospects. J Gastrointest Oncol. 2021;12(S1):S231–9.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Manfredi JJ, Horwitz SB. Taxol: an antimitotic agent with a new mechanism of action. Pharmacol Ther. 1984;25(1):83–125.

    Article  CAS  PubMed  Google Scholar 

  39. Marupudi NI, Han JE, Li KW, Renard VM, Tyler BM, Brem H. Paclitaxel: a review of adverse toxicities and novel delivery strategies. Expert Opin Drug Saf. 2007;6(5):609–21.

    Article  CAS  PubMed  Google Scholar 

  40. Tian Z, Yao W. Albumin-bound paclitaxel: worthy of further study in sarcomas. Front Oncol. 2022;12: 815900.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Lv ZD, Song HM, Niu ZH, Nie G, Zheng S, Xu YY, Gong W, Wang HB. Efficacy and safety of albumin-bound paclitaxel compared to docetaxel as neoadjuvant chemotherapy for HER2-negative breast cancer. Front Oncol. 2021;11: 760655.

    Article  CAS  PubMed  Google Scholar 

  42. Nižnanský Ľ, Osinová D, Kuruc R, Hengerics Szabó A, Szórádová A, Masár M, Nižnanská Ž. Natural taxanes: from plant composition to human pharmacology and toxicity. Int J Mol Sci. 2022;23(24):15619.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Lee SJ, Jeon Y, Lee HW, Kang J, Baik SH, Park EJ. Impact of mitomycin-c-induced neutropenia after hyperthermic intraperitoneal chemotherapy with cytoreductive surgery in colorectal cancer patients with peritoneal carcinomatosis. Ann Surg Oncol. 2022;29(3):2077–86.

    Article  PubMed  Google Scholar 

  44. Lee KW, Maeng CH, Kim TY, Zang DY, Kim YH, Hwang IG, et al. A phase III study to compare the efficacy and safety of paclitaxel versus irinotecan in patients with metastatic or recurrent gastric cancer who failed in first-line therapy (KCSG ST10-01). Oncologist. 2019;24(1):18-e24.

    Article  CAS  PubMed  Google Scholar 

  45. Delhorme JB, Sattler L, Severac F, Triki E, Gross I, Romain B, et al. Prognostic factors of hemorrhagic complications after oxaliplatin-based hyperthermic intraperitoneal chemotherapy: toward routine preoperative dosage of Von Willebrand factor? Eur J Surg Oncol. 2017;43(6):1095–101.

    Article  PubMed  Google Scholar 

  46. Ben Mahmoud IT, Ben Said A, Berguiga S, Houij R, Cherif I, Hamdi A, et al. Incidence and risk factors associated with development of oxalipatin-induced acute peripheral neuropathy in colorectal cancer patients. J Oncol Pharm Pract. 2023;29(2):311–8.

    Article  CAS  PubMed  Google Scholar 

  47. Visacri MB, Duarte NC, Lima TM, de Souza RN, Cobaxo TS, Teixeira JC, et al. Adverse reactions and adherence to capecitabine: a prospective study in patients with gastrointestinal cancer. J Oncol Pharm Pract. 2022;28(2):326–36.

    Article  CAS  PubMed  Google Scholar 

  48. Fan C, Guo H, Chu Y, An G. Efficacy analysis of apatinib combined with chemotherapy in the treatment of advanced second-line gastric cancer. Acta Medica Mediterr. 2022;38(1):711–5.

    Google Scholar 

  49. Fan B, Bu Z, Zhang J, Zong X, Ji X, Fu T, et al. Phase II trial of prophylactic hyperthermic intraperitoneal chemotherapy in patients with locally advanced gastric cancer after curative surgery. BMC Cancer. 2021;21(1):216.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Ge J, Liu T, Lei T, Li X, Song K, Azizi S, Liu H, Tang M. Retrospective cohort study of intraoperative administration of sustained-release 5-fluorouracil implants in advanced gastric cancer patients. Front Pharmacol. 2021;12: 659258.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Batra A, Rigo R, Hannouf MB, Cheung WY. Real-world safety and efficacy of raltitrexed in patients with metastatic colorectal cancer. Clin Colorectal Cancer. 2021;20(2):e75–81.

    Article  PubMed  Google Scholar 

  52. Holden A, Varcoe RL, Jaff MR, Schneider PA, Tepe G, Zeller T. Paclitaxel and mortality: the dose argument is critical. J Endovasc Ther. 2019;26(4):467–70.

    Article  PubMed  Google Scholar 

  53. Shitara K, Matsuo K, Takahari D, Yokota T, Shibata T, Ura T, et al. Neutropenia as a prognostic factor in advanced gastric cancer patients undergoing second-line chemotherapy with weekly paclitaxel. Ann Oncol. 2010;21(12):2403–9.

    Article  CAS  PubMed  Google Scholar 

  54. Shitara K, Yuki S, Tahahari D, Nakamura M, Kondo C, et al. Randomised phase II study comparing dose-escalated weekly paclitaxel vs standard-dose weekly paclitaxel for patients with previously treated advanced gastric cancer. Br J Cancer. 2014;110(2):271–7.

    Article  CAS  PubMed  Google Scholar 

  55. Tamura S, Taniguchi H, Nishikawa K, Imamura H, Fujita J, Takeno A, et al. A phase II trial of dose-reduced nab-paclitaxel for patients with previously treated, advanced or recurrent gastric cancer (OGSG 1302). Ann Oncol. 2019;25(12):2035–43.

    Google Scholar 

  56. Elekonawo FMK, van Eden WJ, van der Plas WY, Ewalds RSG, de Jong LAW, Bremers AJA, et al. Effect of intraperitoneal chemotherapy concentration on morbidity and survival. BJS Open. 2020;4(2):293–300.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Timmins HC, Li T, Trinh T, Kiernan MC, Harrison M, Boyle F, et al. Weekly paclitaxel-induced neurotoxicity in breast cancer: outcomes and dose response. Oncologist. 2021;26(5):366–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Lee H, Park S, Kang JE, Lee HM, Kim SA, Rhie SJ. Efficacy and safety of nanoparticle-albumin-bound paclitaxel compared with solvent-based taxanes for metastatic breast cancer: a meta-analysis. Sci Rep. 2020;10(1):530.

    Article  CAS  PubMed  PubMed Central  ADS  Google Scholar 

Download references

Funding

This work was supported by the National Natural Science Foundation of China, No. 81401515; Zhongnan Hospital of Wuhan University Science, Technology and Innovation Seed Fund, No. znpy2018030; the Program of Excellent Doctoral (Postdoctoral) of Zhongnan Hospital of Wuhan University, No. ZNYB2021013; and “351 talent project (Luojia Young Scholars)” of Wuhan University, Training project for young and middle-aged medical key personnel of Wuhan City and Wuhan Peritoneal Cancer Clinical Medical Center.

National Natural Science Foundation of China,Zhongnan Hospital of Wuhan University Science,Technology and Innovation Seed Fund,the Program of Excellent Doctoral (Postdoctoral) of Zhongnan Hospital of Wuhan University,“351 talent project (Luojia Young Scholars)” of Wuhan University,Training project for young and middle-aged medical key personnel of Wuhan City and Wuhan Peritoneal Cancer Clinical Medical Center

Author information

Authors and Affiliations

  1. Second Clinical College, Wuhan University, Wuhan , Hubei Province, 430070, China

    Jingxiang Zhou

  2. Department of Gastrointestinal Surgery, the Center for Minimally Invasive Surgery of Gastrointestinal Cancer, Hubei Key Laboratory of Tumor Biological Behaviors & Hubei Cancer Clinical Study Center, Wuhan Peritoneal Cancer Clinical Medical Center, Zhongnan Hospital of Wuhan University, No. 169 Donghu Road, Wuchang District, Hubei Province, 430070, China

    Jingxiang Zhou, Xiaopeng Cai, Zhao Lu, Bin Xiong & Chunwei Peng

Authors
  1. Jingxiang Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xiaopeng Cai
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zhao Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Bin Xiong
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Chunwei Peng
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Zhou JX, Liu HB, and Peng CW contributed to manuscript writing and editing, and data collection; Zhou JX, Cai XP, and Lu Z contributed to data analysis; Zhou JX prepared Fig. 1; Xiong B and Peng CW contributed to conceptualization and supervision; all authors have read and approved the final manuscript.

Corresponding author

Correspondence to Chunwei Peng.

Ethics declarations

Ethics Approval

This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Zhongnan Hospital of Wuhan University.

Consent to Participate

Informed consent was obtained from all individual participants included in the study.

Competing Interests

The authors declare no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhou, J., Cai, X., Lu, Z. et al. Short-Term Safety Evaluation of Albumin-Bound Paclitaxel in Intraoperative and Postoperative Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer. J Gastrointest Canc (2024). https://doi.org/10.1007/s12029-024-01031-9

Download citation

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s12029-024-01031-9

Keywords

Search

Navigation